Cellular Intelligence
Boston stem-cell AI company (formerly Somite AI) building a "virtual cell signaling" model to engineer therapeutic cell types.
1. Core Product / Service
Cellular Intelligence (Somite AI / Somite Therapeutics until January 2026) builds DeltaStem, a foundation model for steering human pluripotent stem cells into specific cell types [1][2]. The model uses a Transformer-style architecture to predict a cell's next state from its current state and a sequence of external signals. An active-learning loop then chooses the next experiments according to the model's uncertainty [1]. The goal is to replace slow trial-and-error differentiation protocols with model-designed ones.
Therapeutic directions disclosed at the Series A: beta cells for type 1 diabetes, articular cartilage, satellite (muscle stem) cells for Duchenne muscular dystrophy, and hematopoietic cells for blood disorders [2]. Third-party profiles name programs SMT-M01 (Duchenne) and SMT-B01 (metabolic), but the company has not confirmed them. All programs are at discovery or preclinical stage. Since the 2026 rebrand, the company presents itself mainly as an "AI-native TechBio" model builder [1]. Whether it will keep running its own therapy programs or mostly license the model is an open question.
Wet lab. The company runs its own data factory. A proprietary semi-permeable capsule platform exposes stem cells to ordered sequences of signals and records the state changes they cause [1]. The company reports scaling from a 27,000-condition pilot to more than one million ordered signal combinations during 2025. It also claims more than 1,000x the efficiency of existing methods; both figures are its own and have not been independently verified [1][2]. Boston job posts seek a hands-on hiPSC differentiation Senior Research Associate/Associate Scientist reporting into translational science, and a single-cell/spatial bioinformatics scientist [4]. Lab area, headcount (databases estimate 11-50) and CRO use are undisclosed.
2. Target Users & Pain Points
- Cell-therapy developers and patients: making functional, mature cell types from stem cells at scale is a key bottleneck for cell replacement therapies.
- Pain addressed: differentiation protocols take years of hand-tuning; the company's claim is that a signaling model can search the space of possible protocols far faster.
3. Competitive Landscape
| Player | Approach | Vs. Cellular Intelligence |
|---|---|---|
| xaira-therapeutics | Perturb-seq atlases + X-Cell virtual cell | Gene perturbations rather than signal sequences |
| newlimit | Transcription-factor reprogramming for rejuvenation | Similar pooled screening, different goal |
| retro-biosciences | Cell therapy with in-house GMP | Further along in manufacturing |
| Arc Institute / Tahoe | Open virtual-cell datasets | Data and model providers, not therapy developers |
4. Unique Observations
- Founding date. SEC Form D lists 2023 as the year of incorporation [5]; press accounts describe operations starting in early 2024. The scientific founders' research predates the company.
- Moving from pipeline toward platform. The 2026 name change and white paper emphasize a general signaling model over specific cell therapies. This mirrors a wider pattern in which AI biotechs founded in 2023 or later hedge between owning assets and selling models.
- One of the few small companies to quantify its own throughput. Most young AI biotechs give no wet-lab output numbers. This company reports condition counts, although the numbers are self-reported.
5. Financials / Funding
- Pre-seed/seed (2023-24): roughly $10-15M, inferred from the reported total; investors included Texas Venture Partners [2].
- Series A (2025-05-13): ~$47.5M, led by Khosla Ventures, with SciFi VC, the Chan Zuckerberg Initiative and Ajinomoto [2][5].
- Strategic: AMD Ventures (2025-08, undisclosed) [1].
- Total: >$62M per trade press [1]. One third-party site reports a 2026 round led by Novo Nordisk; this is unconfirmed.
6. People & Relationships
- CEO & co-founder: Micha Breakstone (co-founder of Chorus.ai) [3].
- Co-founders: Jonathan Rosenfeld (MIT), Olivier Pourquie and Allon Klein (Harvard Medical School); some sources also list Jay Shendure [3].
- Advisors (2026): Bob Langer, Yann LeCun, Jens Nielsen, Fabian Theis (reported).
- Investors: Khosla, CZI, SciFi VC, AMD Ventures.
- Peers: xaira-therapeutics, newlimit, insitro, recursion-pharmaceuticals.
Sources
- [1] BioPharmaTrend, "Somite AI rebrands as Cellular Intelligence" (2026-01; accessed 2026-10-14); Bio-IT World (2026-01-08)
- [2] Biohub / company Series A release (2025-05-13; accessed 2026-10-14); Pulse 2.0
- [3] Globes, "AI cell therapy development co Somite raises $47m" (2025-05; accessed 2026-10-14)
- [4] Cellular Intelligence job postings (startup.jobs, Built In Boston; accessed 2026-10-14)
- [5] SEC Form D, CIK 2075078 (2025-11-26; accessed 2026-10-14)